Vandria SA

AWARDS DINNER Our CSO Pénélope Andreux is in London to attend the Informa LSX - partnering for Life Science eXecutives 2024 European Lifestars Awards - Celebrating Life Science Leaders dinner at the City Central @ Honourable Artillery Company where she is looking forward to networking with other finalists and colleagues from the life sciences industry. Pénélope was selected as a finalist in the Women Led Businesses Category. A key member of Vandria’s Executive Team, she is a mitochondrial expert, she leads our team developing first-in-class small molecule mitophagy inducers, capitalizing on 15 years of discovery science, to treat diseases of aging including neurological disorders. Competition is fierce – so good luck to Pénélope and the other finalists. The list of finalists can be viewed here - https://lnkd.in/dNeDbkCx #awards #leadership #drugdiscovery #healthyaging #neuroscience #mitophagy 

APPOINTMENT we are absolutely thrilled to welcome Professor Li-Huei Tsai to our team. A world recognised expert in #Alzheimer’s Research and brain aging she has agreed to become a consultant to Vandria. Currently Director of The Picower Institute for Learning and Memory and Professor of neuroscience in the MIT Brain and Cognitive Sciences, she has co-founded the Aging Brain Initiative and is co-director of the Alana Down Syndrome Center. A Fellow of the American Association for the Advancement of Science (AAAS) and National Academy of Inventors, and a Member of the National Academy of Medicine and the American Academy of Arts & Sciences, during her career she has received multiple awards and recognition for her outstanding contribution to neuroscience research and the biological mechanisms of aging. We look forward to her input and insights as we advance our first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Already our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer is about to enter the clinic for mild cognitive disorders. It has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. Find more information on our science and portfolio at www.vandria.com #MitochonrialTherapeutics #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation #Biotech #Aging

Our CEO Klaus Dugi and Head of BD and Finance Peter Harboe-Schmidt are preparing for Informa Connect #BioEurope in Stockholm 4-6 October. If you plan to be there and would like to meet up to hear about our progress with our mitophagy inducers, do get in touch. They will be looking forward to catching up with colleagues from the life sciences and healthcare industry, and network with biotech and pharma industry colleagues and investors. Our plans are well advanced to start clinical development in the coming weeks for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer and we are already planning our series B to fund further trials and pipeline growth. To meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio at www.vandria.com #Partnering #Investment #LifeScienes #MitochondrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

Today is World Alzheimer’s Day. A day to celebrate recent advances in treatments for Alzheimer’s and to recognize the continuing need to develop new treatments for the >55million people worldwide and their families living with Alzheimer’s. Vandria is advancing a pipeline of first-in-class mitophagy inducers that rejuvenate cells through mitochondrial renewal. Often referred to as the powerhouse of the cell, mitochondria play a pivotal role in energy production and scientists have demonstrated links between mitochondrial dysfunction and neurological disorders, including Alzheimer’s. Our lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. It is on track to enter clinical trials in the coming weeks. If you’re intrigued by our science, you can find out more about our portfolio at www.vandria.com #WorldAlzheimersDay #Alzheimers #Parkinsons #PD #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation

AWARD NEWS Congratulations to our CSO Pénélope Andreux who has been selected as finalist in the LSX - partnering for Life Science eXecutives 2024 European Lifestars Awards - Celebrating Life Science Leaders Awards Informa. A mitochondrial expert, Pénélope lead our team developing first-in-class small molecule mitophagy inducers, capitalizing on 15 years of discovery science, to treat diseases of aging including neurological disorders. Pénélope orchestrated the company’s move this year to dedicated lab facilities at @Superlab Suisse on the Biopôle Lausanne campus. Under her leadership, the team generated compelling scientific data which attracted new investors, Hevolution Foundation and Dolby Family Ventures into our Series A financing joining our founding investor #NDCapital and bringing the total raised to $30.7M (CHF28.3M). She has also been instrumental in attracting non-dilutive grants from #Eurostars and Innosuisse totaling €3.8 M. Pénélope is a key member of Vandria’s Executive Team working alongside our CEO Klaus Dugi, MD to prepare our lead program, VNA-318 for our first-in-man clinical trial for cognitive decline, due to start later this year. Competition is fierce – so good luck to Pénélope and other finalists. Winners will be announced on Monday 18 November at the Awards Dinner in London. The list of finalist can be viewed here - https://lnkd.in/dNeDbkCx #awards #leadership #drugdiscovery #healthyaging #neuroscience #mitophagy 

𝐌𝐚𝐥𝐚𝐝𝐢𝐞𝐬 𝐧𝐞𝐮𝐫𝐨𝐝é𝐠é𝐧é𝐫𝐚𝐭𝐢𝐯𝐞𝐬: 𝐧𝐨𝐮𝐯𝐞𝐥𝐥𝐞 𝐥𝐞𝐯é𝐞 𝐝𝐞 𝐟𝐨𝐧𝐝𝐬 𝐩𝐨𝐮𝐫 𝐕𝐚𝐧𝐝𝐫𝐢𝐚 La start-up lausannoise Vandria SA prévoit de démarrer ses essais cliniques en phase I et anticipe déjà une nouvelle levée de fonds pour 2025. Par Ghislaine Bloch #investissement #pharma #croissance #fonds #développement

APPOINTMENT In association with the recently announced second closing of our series A financing totaling $30.7M (CHF28.3M), we are delighted to welcome Jens Eckstein, Investment Partner at Hevolution Foundation to our board of directors. Co-Founder of innovative life science and healthcare IT companies, Jens plays an active role in mentoring life science entrepreneurs and start-up teams. He brings >20 years’ experience of venture capital funding of earlier-stage biopharmaceutical companies, technology transfer, and board of directors’ responsibilities, together with 10 years of operational and research management experience in drug discovery and biotechnology. Headquartered in Riyadh with a North American hub in Boston, Hevolution Foundation is focused on investing in innovative science to support healthy aging. Read the full press release HERE https://lnkd.in/eE6QGd-K #appointment #venturecapital #financing #seriesA #drugdiscovery #healthyaging #mitophagy

FINANCING NEWS We are delighted to announce the second closing of our series A financing bringing the final amount raised to date to $30.7M (CHF28.3M. We welcome new institutional investors Hevolution Foundation and Dolby Family Ventures who have joined our founding venture investor #NDCapital. Hevolution is focused on investing in innovative science to support healthy aging. Dolby Family Ventures, in life sciences, invests in early-stage precision neuroscience and platform companies. Vandria is a great fit to their portfolios, as we are developing first-in-class small molecule mitophagy inducers against a novel target to rejuvenate cells and treat age-related and chronic diseases. Since the first Series A close in December at $20.6M (CHF 18M), we have made rapid progress: · Developed our platform and portfolio · Advanced our lead program, VNA-318, a patent-protected, brain-penetrant, first-in-class mitophagy inducer. VNA-318 is on track to enter clinical trials in Europe in the coming weeks · Expanded our team and moved to dedicated lab facilities at Superlab Suisse on the Biopôle Lausanne campus ·        Secured CHF4.2M in prestigious non-dilutive funding: two Innosuisse grants to support VNA-318 and an #Eurostars grant to support the generation of preclinical data for mitophagy drug candidates in our muscle program   Our CEO Klaus Dugi, said: “This financing supports our transformation into a clinical stage company as we progress further in clinical development with runway with the series A to complete the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) first-in-man Phase 1 study of VNA-318 and to initiate three parallel Phase 1b / 2a efficacy studies in 2025, subject to positive progress in the Phase 1 and regulatory approvals.” Read the full press release HERE https://lnkd.in/eE6QGd-K #venturecapital #financing #seriesA #drugdiscovery #healthyaging #neuroscience #mitophagy

June is Alzheimer’s & Brain Awareness Month. At Vandria we are passionate about developing life changing therapies to treat age-related and chronic diseases, with a focus on neurological disorders. We are at the vanguard of mitochondrial therapeutics, developing first-in-class mitophagy inducers that rejuvenate cells. Our lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. It is on track to enter clinical trials this summer. Worldwide, more than 55 million people are living with Alzheimer's or another dementia. Join the Alzheimer's Association in going purple and raising awareness this June. The more that people know about Alzheimer's, the more action we inspire. Let’s End Alzheimer’s - #ENDALZ. If you’re intrigued by our science you can find out more about our portfolio at www.vandria.com #Alzheimers #ParkinsonsDisease #PD #MitochondrialTherapeutics #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation

Our CEO Klaus Dugi and Head of BD & Finance Peter Harboe-Schmidt are looking forward to attending BIO International Convention next week in San Diego 3-6 June. Plans are well advanced to start clinical trials for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer this summer and we are already planning our series B to fund further trials and pipeline growth. If you’d like to meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio HERE www.vandria.com #Partnering #investment #lifescienes #MitochonrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy